Multifactorial 1, 3, 4‐Oxadiazole Derivatives as Cholinesterase and Glycogen Synthase Kinase‐3 β Inhibitors for Targeting Alzheimer's Disease: QSAR‐Based Virtual Screening, MD Docking, Free Energy Analysis, ADMET, and DFT Studies

Documenti analoghi

• In Silico Discovery of 1,3,4‐Thiadiazole Derivatives as VEGFR‐2 Inhibitors for Breast Cancer Liver Metastasis via QSAR modeling, Molecular Docking, ADMET, and DFT Studies
  di: Pragya Gawande, et al.
  Pubblicazione: (2026)
• Predictive QSAR Models Followed by Toxicity, Molecular Docking, and Molecular Dynamics Simulation in Search of Azole Derivatives as AChE Inhibitors for the Treatment of Alzheimer's Disease
  di: Kajal Gupta, et al.
  Pubblicazione: (2025)
• Discovery of Azole‐Based COX‐2 Inhibitors Targeting Neuroinflammation in Alzheimer's Disease Via Integrated QSAR‐Based Virtual Screening, Molecular Docking, and Molecular Dynamics
  di: Sanjana Das, et al.
  Pubblicazione: (2026)
• Origin of the OECD Principles for QSAR Validation and Their Role in Changing the QSAR Paradigm Worldwide: An Historical Overview
  di: Paola Gramatica
  Pubblicazione: (2025)
• 1,3,4‐Thiadiazole Derivatives as VEGFR‐2 Inhibitors and Its Molecular Insight for Cancer Therapy
  di: Pragya Gawande, et al.
  Pubblicazione: (2025)